Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences reached its enrollment target of 164 evaluable patients across 15 clinical sites in the NANOPULSE-AF IDE pivotal study of the nPulse Cardiac Catheter System for drug-resistant paroxysmal atrial fibrillation. Enrollment closed three months ahead of the original 9-month timeline, with investigators citing rapid site activation and strong operator enthusiasm for the nsPFA technology.
Key figures
- Drug Name
- nPulse Cardiac Catheter System
- Phase Of Trial
- IDE pivotal (NANOPULSE-AF)
- Timeline note
- reached enrollment target three months ahead of original 9-month timeline
- Clinical sites
- 15
- Patients enrolled
- 164
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.